BR112023023670A2 - Composição farmacêutica para prevenir ou tratar fibrose - Google Patents

Composição farmacêutica para prevenir ou tratar fibrose

Info

Publication number
BR112023023670A2
BR112023023670A2 BR112023023670A BR112023023670A BR112023023670A2 BR 112023023670 A2 BR112023023670 A2 BR 112023023670A2 BR 112023023670 A BR112023023670 A BR 112023023670A BR 112023023670 A BR112023023670 A BR 112023023670A BR 112023023670 A2 BR112023023670 A2 BR 112023023670A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
prevent
fibrosis
treat fibrosis
component
Prior art date
Application number
BR112023023670A
Other languages
English (en)
Portuguese (pt)
Inventor
Hee Lee Caroline
Jeong Bae Da
Hyeon Kim Ji
Seok Park Joon
Jae Cho Min
Young Park Min
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of BR112023023670A2 publication Critical patent/BR112023023670A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112023023670A 2021-05-13 2022-05-02 Composição farmacêutica para prevenir ou tratar fibrose BR112023023670A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210062252 2021-05-13
PCT/KR2022/006231 WO2022240036A1 (ko) 2021-05-13 2022-05-02 섬유화증의 예방 또는 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
BR112023023670A2 true BR112023023670A2 (pt) 2024-01-30

Family

ID=84029268

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023670A BR112023023670A2 (pt) 2021-05-13 2022-05-02 Composição farmacêutica para prevenir ou tratar fibrose

Country Status (16)

Country Link
US (1) US20240238278A1 (ja)
EP (1) EP4338734A1 (ja)
JP (1) JP2024516021A (ja)
KR (1) KR20220154616A (ja)
CN (1) CN117320718A (ja)
AR (2) AR125885A1 (ja)
AU (1) AU2022274469A1 (ja)
BR (1) BR112023023670A2 (ja)
CA (1) CA3213455A1 (ja)
CL (1) CL2023003345A1 (ja)
CO (1) CO2023015482A2 (ja)
EC (1) ECSP23086047A (ja)
MX (1) MX2023013405A (ja)
PE (1) PE20241171A1 (ja)
TW (1) TW202310839A (ja)
WO (1) WO2022240036A1 (ja)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2320905T1 (sl) * 2008-08-11 2017-10-30 Glaxosmithkline Llc Corporation Service Company Novi adeninski derivati
AR110963A1 (es) 2017-02-07 2019-05-22 Dae Woong Pharma Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende
JP2021517558A (ja) * 2018-03-19 2021-07-26 シェオ ファーマスーティカルズ 特発性肺線維症を治療するための方法および組成物

Also Published As

Publication number Publication date
CL2023003345A1 (es) 2024-06-07
JP2024516021A (ja) 2024-04-11
CA3213455A1 (en) 2022-11-17
AR125886A1 (es) 2023-08-23
AU2022274469A1 (en) 2023-09-21
EP4338734A1 (en) 2024-03-20
WO2022240036A1 (ko) 2022-11-17
AR125885A1 (es) 2023-08-23
MX2023013405A (es) 2023-11-27
TW202310839A (zh) 2023-03-16
PE20241171A1 (es) 2024-05-28
KR20220154616A (ko) 2022-11-22
ECSP23086047A (es) 2023-12-29
US20240238278A1 (en) 2024-07-18
CO2023015482A2 (es) 2023-11-30
CN117320718A (zh) 2023-12-29

Similar Documents

Publication Publication Date Title
BRPI1012219C1 (pt) produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para prevenir formação de biofilme em um ambiente, para tratar uma infecção microbiana por profilaxia ou terapia, e para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina
BR112022012637A2 (pt) Composto de piridazinil-tiazolcarboxamida, composição farmacêutica e inibidor da dgk ¿ que compreendem o mesmo e uso do dito composto para tratar câncer relacionado à ativação das células imunes ou câncer tendo resistência à terapia com anticorpo anti-pd-1 / anticorpo anti-pd-l1
BR112018001640A2 (pt) combinação de antagonista da pd-1 com um inibidor de egfr
BR112013010021A2 (pt) combinações farmacêuticas para o tratamento de distúrbios metabólicos.
BR112023022451A2 (pt) Composto triazina substituído
BR112017023805A2 (pt) formulações de tpp1 e métodos para o tratamento de doença lcn2
BR112022022578A2 (pt) Novas composições e métodos de tratar doença covid-19
BR112023019668A2 (pt) Composição farmacêutica para prevenir ou tratar fibrose
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
BR112021017314A2 (pt) Uso de extrato de elaeocarpus sylvestris
BR112012024887A2 (pt) grânulos de quitosana, preenchedor, processo para preparar os grânulos de quitosana, kit e disposto de injeção
BR112023025916A2 (pt) Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção
BR112019005985A2 (pt) composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico
BR112018017233A2 (pt) uso de i. butyriciproducens e/ou e. hallii, e, composição
BR112023025738A2 (pt) Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção
BR112021024109A2 (pt) Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática
WO2015035410A8 (en) Cancer therapy
BR112023016682A2 (pt) Terapia de combinação de obicetrapibe e ezetimiba para uso em pacientes intolerantes a estatina sofrendo de hiperlipidemia ou dislipidemia mista
BRPI0923373B8 (pt) composições farmacêuticas compreendendo uma combinação de insulina com derivados de triazina, e uso da dita combinação
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
BR112023023670A2 (pt) Composição farmacêutica para prevenir ou tratar fibrose
BR112022018396A2 (pt) Método de tratamento ou prevenção para insuficiência cardíaca crônica
BR112022019518A2 (pt) Composição farmacêutica para prevenir ou tratar mucosite induzida por radioterapia, quimioterapia, ou uma combinação das mesmas, que compreende derivados de glp-2 ou um conjugado de atuação duradoura do mesmo
BR112022022305A2 (pt) Combinação farmacêutica que compreende tno155 e nazartinibe